Xiaoyong Zhang

Key Laboratory Of Infectious Diseases Research In South China
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Anti-RPL30 as a novel biomarker for enhanced diagnosis of autoantibody-negative primary biliary cholangitis.

Anti-RPL30 as a novel biomarker for enhanced diagnosis of autoantibody-negative primary biliary cholangitis.

Journal: World journal of gastroenterology

Published: January 07, 2025

CD163 impairs HBV clearance in mice by regulating intrahepatic T cell immune response via an IL-10-dependent mechanism.

CD163 impairs HBV clearance in mice by regulating intrahepatic T cell immune response via an IL-10-dependent mechanism.

Journal: Antiviral research

Published: September 09, 2024

AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation.

AXIN1 boosts antiviral response through IRF3 stabilization and induced phase separation.

Journal: Signal transduction and targeted therapy

Published: April 22, 2024

Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc-ODC1 nexus.

Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc-ODC1 nexus.

Journal: Cancer & metabolism

Published: September 01, 2023

HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway.

HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway.

Journal: Journal of translational medicine

Published: February 15, 2023

Targeting cIAPs attenuates CCl4-induced liver fibrosis by increasing MMP9 expression derived from neutrophils.

Targeting cIAPs attenuates CCl4-induced liver fibrosis by increasing MMP9 expression derived from neutrophils.

Journal: Life sciences

Published: October 08, 2021

Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

Journal: Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases

Published: September 20, 2019

Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B.

Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B.

Journal: BMC infectious diseases

Published: September 05, 2018

Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection?

Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection?

Journal: Virologica Sinica

Published: August 09, 2018

Innate immune recognition of hepatitis B virus.

Innate immune recognition of hepatitis B virus.

Journal: World journal of hepatology

Published: June 10, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026